iTeos Therapeutics Inc. (ITOS): Price and Financial Metrics


iTeos Therapeutics Inc. (ITOS): $20.03

0.17 (+0.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ITOS Stock Price Chart Interactive Chart >

Price chart for ITOS

ITOS Price/Volume Stats

Current price $20.03 52-week high $47.61
Prev. close $19.86 52-week low $17.43
Day low $19.50 Volume 186,200
Day high $20.19 Avg. volume 279,404
50-day MA $23.47 Dividend yield N/A
200-day MA $28.76 Market Cap 703.13M

iTeos Therapeutics Inc. (ITOS) Company Bio


iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.


ITOS Latest News Stream


Event/Time News Detail
Loading, please wait...

ITOS Latest Social Stream


Loading social stream, please wait...

View Full ITOS Social Stream

Latest ITOS News From Around the Web

Below are the latest news stories about iTeos Therapeutics Inc that investors may wish to consider to help them evaluate ITOS as an investment opportunity.

iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021

Updated results from a dataset of 43 patients showed durable responses and stable disease greater than six months with inupadenant monotherapy in five patients with advanced solid tumors, including previously reported confirmed partial responses in patients with checkpoint-inhibitor resistant melanoma and heavily pretreated castrate-resistant prostate cancer, and a newly reported patient with heavily pretreated non-small cell lung cancer who had stable disease lasting more than 10 months Prelimi

Yahoo | June 4, 2021

iTeos to Present at the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 8:00 a.m. ET. A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation. About iTeos Therapeutics, Inc. iTeos Therapeutics is a clinical-stage biopharmaceutical compa...

Yahoo | May 26, 2021

iTeos Therapeutics' (ITOS) CEO Michel Detheux on Q1 2021 Results - Earnings Call Transcript

iTeos Therapeutics, Inc. (ITOS) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Ryan Baker – Head of Investor Relations Michel Detheux – President and Chief Executive Officer Joe Lager – Chief Medical Officer Matthew Gall – Chief Financial Officer Conference Call Participants Chris Raymond –...

SA Transcripts on Seeking Alpha | May 14, 2021

iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors

CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 03, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the appointment of Tony Ho, M.D., and Robert Iannone, M.D., M.S.C.E., to its Board of Directors. They will expand the clinical drug development and strategy expertise of iTeos Board with their track record in leading pharma and biotech companies. “We are thrilled to welcome Tony and Robert to our board as we advance our highly innovative immuno-oncology pipeline programs through clinical development,” said David Hallal, Chairman of the Board of iTeos Therapeutics. “Tony and Robert bring ex...

Yahoo | May 3, 2021

We're Not Worried About iTeos Therapeutics' (NASDAQ:ITOS) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | April 26, 2021

Read More 'ITOS' Stories Here

ITOS Price Returns

1-mo -18.18%
3-mo -42.51%
6-mo -35.86%
1-year N/A
3-year N/A
5-year N/A
YTD -40.77%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6541 seconds.